Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
In the clinic for April 25, 2024
BioWorld
Related Posts
Post navigation
Previous Post
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Next Post
Gain touts positive Phase I results for Parkinson’s therapy
Latest Articles
Clear Filters
October 12, 2020
Gain Therapeutics to Present New Preclinical Data on Brain Penetrant Allosteric Regulators at the 14th Meeting of the European Working Group on Gaucher Disease
Read More
May 24, 2022
H.C. Wainwright Global Investment Conference
Read More
March 9, 2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Read More
Close
